IL161587A0 - Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient - Google Patents

Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient

Info

Publication number
IL161587A0
IL161587A0 IL16158702A IL16158702A IL161587A0 IL 161587 A0 IL161587 A0 IL 161587A0 IL 16158702 A IL16158702 A IL 16158702A IL 16158702 A IL16158702 A IL 16158702A IL 161587 A0 IL161587 A0 IL 161587A0
Authority
IL
Israel
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
IL16158702A
Other languages
English (en)
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161587(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of IL161587A0 publication Critical patent/IL161587A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL16158702A 2001-10-24 2002-10-22 Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient IL161587A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
IL161587A0 true IL161587A0 (en) 2004-09-27

Family

ID=26010444

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16158702A IL161587A0 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
IL161587A IL161587A (en) 2001-10-24 2004-04-22 Pharmaceutical composition containing 3 - (3 - dimethylamino - 1 - ethyl - 2 - methyl - propyl) phenol and providing delayed release of the active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161587A IL161587A (en) 2001-10-24 2004-04-22 Pharmaceutical composition containing 3 - (3 - dimethylamino - 1 - ethyl - 2 - methyl - propyl) phenol and providing delayed release of the active ingredient

Country Status (28)

Country Link
US (7) US20050058706A1 (Direct)
EP (1) EP1439829B1 (Direct)
JP (2) JP4758064B2 (Direct)
KR (1) KR100958045B1 (Direct)
CN (1) CN100402021C (Direct)
AR (1) AR036943A1 (Direct)
AT (1) ATE303802T1 (Direct)
AU (1) AU2002349001C1 (Direct)
BR (1) BRPI0213653B8 (Direct)
CA (1) CA2464578C (Direct)
CO (1) CO5570662A2 (Direct)
CY (1) CY2012022I1 (Direct)
DE (1) DE50204198D1 (Direct)
DK (1) DK1439829T3 (Direct)
EC (1) ECSP045102A (Direct)
ES (1) ES2248622T3 (Direct)
HU (1) HU230161B1 (Direct)
IL (2) IL161587A0 (Direct)
MX (1) MXPA04003742A (Direct)
MY (1) MY127797A (Direct)
NO (2) NO331896B1 (Direct)
NZ (1) NZ532999A (Direct)
PE (1) PE20030527A1 (Direct)
PL (1) PL216535B1 (Direct)
PT (1) PT1439829E (Direct)
SI (1) SI1439829T1 (Direct)
WO (2) WO2003035054A1 (Direct)
ZA (1) ZA200403928B (Direct)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DK1562567T3 (en) * 2002-11-22 2017-07-17 Gruenenthal Gmbh Combination of selected analgesics with COX II inhibitors
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE502004004205D1 (de) * 2003-08-06 2007-08-09 Gruenenthal Gmbh Gegen missbrauch gesicherte darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
PT1612203E (pt) 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005259478B2 (en) * 2004-07-01 2010-07-15 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SI2012763T1 (sl) * 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
AU2007247481B2 (en) * 2006-04-28 2013-02-14 Grunenthal Gmbh Pharmaceutical combination comprising 3- ( 3-Dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101784777B1 (ko) * 2007-11-23 2017-11-06 그뤼넨탈 게엠베하 타펜타돌 조성물
SI2240431T1 (sl) * 2007-12-07 2017-05-31 Gruenenthal Gmbh Kristalinične modifikacije (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
EP2352494B1 (en) 2008-10-30 2019-10-09 Grünenthal GmbH Novel and potent tapentadol dosage forms
PE20120572A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
EP2531176B1 (en) * 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
BR112012031836A2 (pt) * 2010-06-15 2016-11-08 Gruenenthal Gmbh combinação farmacêutica para o tratamento da dor
AU2011273907B2 (en) 2010-06-30 2015-03-19 Grunenthal Gmbh Tapentadol for use in the treatment of Irritable Bowel Syndrome
EP3650439B1 (en) 2010-07-23 2021-02-24 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
AU2011297892B2 (en) 2010-09-02 2014-05-29 Grunenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
PL2680834T3 (pl) 2011-03-04 2018-03-30 Grünenthal GmbH Półstała wodna kompozycja farmaceutyczna zawierająca tapentadol
CN103501775A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
EP3449917A3 (en) 2011-04-05 2019-06-05 Grünenthal GmbH Tapentadol for preventing chronification of pain
PL2694050T3 (pl) 2011-04-05 2020-03-31 Grünenthal GmbH Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
HRP20171570T1 (hr) 2011-04-29 2017-11-17 Grünenthal GmbH Tapentadol za sprječavanje i liječenje depresije i tjeskobe
NO2736495T3 (Direct) 2011-07-29 2018-01-20
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
ES2663403T3 (es) * 2011-07-29 2018-04-12 Grünenthal GmbH Administración intratecal o epidural de 3-[(1S,2S)-3-(dimetilamino)-1-etil-2-metilpropil]fenol
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
US20180369151A1 (en) * 2017-05-29 2018-12-27 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
EP3875080B1 (en) 2020-03-02 2025-12-31 Grünenthal GmbH EXTENDED-RELEASE DOSAGE FORM OF PHOSPHORIC ACID SALT OF TAPENTADOL
HRP20240081T1 (hr) * 2020-03-02 2024-05-24 Grünenthal GmbH Oblik doziranja koji pruža produljeno oslobađanje soli tapentadol-fosforne kiseline
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
MX2022010780A (es) 2020-03-02 2022-09-26 Gruenenthal Gmbh Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol.
BR112022018572A2 (pt) 2020-03-16 2022-11-01 Gruenenthal Gmbh Comprimido sulcado
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
ES2927147T3 (es) * 2020-11-10 2022-11-02 Gruenenthal Gmbh Forma de dosificación que proporciona liberación prolongada de una sal de Tapentadol con ácido L-(+)-tartárico
MX2023005472A (es) 2020-11-10 2023-05-22 Gruenenthal Gmbh Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5612183A (en) 1983-01-10 1997-03-18 Gen-Probe Incorporated Method for determining the effect of antimicrobial agents on growth using ribosomal nucleic acid subunit subsequence specific probes
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
DE69433055T2 (de) 1993-11-17 2004-02-26 Lequio Pharma Co.Ltd., Naha Zusammensetzung zum heilen von verletztem gewebe, verfahren für ihre herstellung und ihre verwendung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
EP0859603B1 (en) * 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
EP0998271B3 (en) * 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
CN102716101A (zh) * 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
HK1068539A1 (en) 2005-04-29
ECSP045102A (es) 2004-06-28
HU230161B1 (en) 2015-09-28
BRPI0213653B1 (pt) 2018-04-03
NO2012007I2 (no) 2013-01-02
WO2003035053A1 (de) 2003-05-01
PE20030527A1 (es) 2003-07-26
KR100958045B1 (ko) 2010-05-17
SI1439829T1 (sl) 2006-02-28
JP4758064B2 (ja) 2011-08-24
AU2002349001C1 (en) 2022-04-14
US11007156B2 (en) 2021-05-18
US20130237608A1 (en) 2013-09-12
ATE303802T1 (de) 2005-09-15
US20120034304A1 (en) 2012-02-09
JP2010280697A (ja) 2010-12-16
US20180221308A1 (en) 2018-08-09
US20050058706A1 (en) 2005-03-17
PL216535B1 (pl) 2014-04-30
MY127797A (en) 2006-12-29
DK1439829T3 (da) 2005-10-10
ES2248622T3 (es) 2006-03-16
EP1439829A1 (de) 2004-07-28
BR0213653A (pt) 2004-10-26
AU2002349001B2 (en) 2003-05-06
MXPA04003742A (es) 2004-07-23
CA2464578C (en) 2011-10-11
CN100402021C (zh) 2008-07-16
NO2012007I1 (no) 2012-05-21
AR036943A1 (es) 2004-10-13
BRPI0213653B8 (pt) 2021-05-25
DE50204198D1 (de) 2005-10-13
CA2464578A1 (en) 2003-05-01
CN1607947A (zh) 2005-04-20
NZ532999A (en) 2007-06-29
EP1439829B1 (de) 2005-09-07
NO20041924L (no) 2004-05-11
US20170087103A1 (en) 2017-03-30
ZA200403928B (en) 2005-07-27
CY2012022I2 (el) 2015-08-05
NO331896B1 (no) 2012-04-30
US20200038344A1 (en) 2020-02-06
PL369756A1 (en) 2005-05-02
JP2005506367A (ja) 2005-03-03
US20160151309A1 (en) 2016-06-02
PT1439829E (pt) 2005-11-30
WO2003035054A1 (de) 2003-05-01
HUP0402104A2 (hu) 2005-03-29
KR20040047964A (ko) 2004-06-05
IL161587A (en) 2009-12-24
CO5570662A2 (es) 2005-10-31
CY2012022I1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
IL161587A0 (en) Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
IL155293A0 (en) Delayed release pharmaceutical formulations
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HUP0302949A3 (en) Active ingredient combinations comprising insecticidal and acaricidal properties and use thereof
HUP0401911A3 (en) Pesticidal formulations and their use
HUP0303454A3 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
HUP0500127A3 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
HUP0303260A3 (en) Agrochemical formulations, preparation and use thereof
AU2002340573A8 (en) Powdery active ingredient formulations
GB0119848D0 (en) Delayed and sustained drug release
HUP0202847A3 (en) Synergetic insecticidal and acaricidal active ingredient combinations preparation and use thereof
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
HUP0301582A3 (en) Calcilytic compounds and pharmaceutical compositions containing them
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
AU2002346860A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002322424A8 (en) Novel methods and formulations for administration of active agents